Publications by authors named "Teruo Sawada"
Article Synopsis
- Cutaneous warts are caused by the human papilloma virus (HPV), and the study explored the effects of FIT039, a CDK9 inhibitor, on these warts using a skin patch.
- In a phase I/II clinical trial, two different concentrations of FIT039 patches (1% and 3%) were tested for safety and efficacy, with minimal adverse reactions reported and concentrations remaining very low in patients.
- The results indicated that while the 1% FIT039 patch showed no change in wart size after one week, the 3% patch resulted in smaller wart areas, suggesting potential for further research on using FIT039 for treating cutaneous warts.
Cervical cancer is one of the leading causes of cancer-related deaths among women worldwide. The purpose of this study is to assess the therapeutic effect of the newly developed cyclin-dependent kinase 9 (CDK9) inhibitor FIT-039 on cervical neoplasia induced by human papillomavirus (HPV) infection. We examined FIT-039 for its effect on HPV gene expression in HPV cervical cancer cells.
View Article and Find Full Text PDFObjective: The purpose of this study was to compare the efficacy and tolerability of combination therapy of ezetimibe and atorvastatin in patients with high LDL cholesterol that had not reached the lipid management target value with 10 mg atorvastatin monotherapy, against increasing the dose to 20 mg atorvastatin or switching to 2.5 mg rosuvastatin.
Design Setting And Participants: This was an open-label, randomized, multicenter, 3-parallel-group comparison trial at 23 community hospitals and clinics in Japan (enrollment period March 2009 to May 2010) in 125 patients with high LDL cholesterol.